Newcelx Ltd. · NASDAQ:NCEL
Newcelx — Investor Presentation (January 2026)
27 slides from Newcelx's investor presentation, Jan 29, 2026
Slide 1: Regenerative Medicine to Cure Type 1 Diabetes
JANUARY 2026 ( NASDAQ : NCEL ) ©2026 N EW C EL X L TD . REGENERATIVE MEDICINE TO CURE TYPE 1 DIABETES 72:$5'$&85()257<3( ',$%(7(6
Slide 2: Disclaimer
Disclaimer This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws . For example, NewCelX Ltd . (“ NewCelX ,” “we,” “our” or “us”) is using forward - looking statements when we di
Slide 3: Cure Type 1 Diabetes
3 Cure Type 1 diabetes We are a clinical stage regenerative medicine company focused on Type 1 Diabetes Cell Therapy using IsletRx Plus highly specialized stem - cell derived insulin producing cells as cell replacement therapy 3 72:$5'$&85()257<3( ',$%(7(6
Slide 4: The NewcelX Factor Today, Value Driven
The NewcelX Factor Today, Value Driven CORE PLATFORM Stem Cell Technology • GMP Manufacturing • Clinical - Grade Bio - Banks • Off - the - Shelf Therapies • Scalable Multi - Indication Platform PRIMARY VALUE DRIVER Type 1 Diabetes IsletRx • Insulin - dependent diabetes • Pre - clinical / IND - enabl
Slide 5: Need for functional beta-cell replacement in Type 1 diabetes
• Healthy and functional islet cells can produce and secrete insulin in a regulated manner • Cadaveric donor islet cell therapy is a safe and clinically validated treatment for Insulin - Dependent Diabetes 1 • Patients treated achieved Insulin independence for ~2 years following treatment 4 • Main c
Slide 6: Global Market and Facts For Type 1 Diabetes
Global Market and Facts For Type 1 Diabetes Living with Type 1 Diabetes worldwide 9.5 million people 1. 8 million Children and adolescents below 20 years have type 1 diabetes 2 174,000 Premature Deaths attributed to Type 1 Diabetes 813B$ Lifetime cost in US for health expenditure in Type 1 diabetes
Slide 7: An Active Market – Key Recent Transactions, Developments & Validations
An Active Market – Key Recent Transactions, Developments & Validations 2019 Semma Therapeutics 2019 Acquired by Vertex $950M Preclinical islet cell therapy 1 Diabetes 20 21 Diabetes and cell therapy Sana Biotechnology 2021 Aspect Biosystems /Novo Nordisk Lead asset licensing deal $75M upfr ont $750M
Slide 8: Major Technology Competition – Type 1 Diabetes
Major Technology Competition – Type 1 Diabetes Technology Cell source Development stage Product Company Cell Therapy Technology Competition Liver infusion + immunosuppression Stem cells - derived Islets Phase 1 2 - 3 VX - 880 Vertex 1 Omentum + immunosuppression Stem cells - derived Islets Phase 1 S
Slide 9: Differentiation of PSCs into islet-like clusters
Differentiation of PSCs into islet - like clusters 9 Pluripotent Definitive Endoderm Endocrine progenitors Posterior Foregut Pancreatic progenitors Primitive gut tube Immature Endocrine S S S S S S S 7 - stage protocol, ~28 days for production Recapitulating pancreatic development stages Final enric
Slide 10: iTOL – With Enriched IsletRx Plus Cells
iTOL 102 – With Enriched IsletRx Plus Cells • Functional insulin - secreting islet cells • Physiologic glucose - responsive insulin release • Unlimited and standardized cell supply • Efficacy and safety in preclinical studies • Durable – long term function in diabetic animal models • Localized immun
Slide 11: iTOL-102: Kadimastem & iTolerance co-development
• Regenerative medicine without the need for life - long immunosuppression • Leverages the naturally occurring protein , Fas Ligand ( FasL ) • Creates localized immune privilege environment • BIRD Grant funded (~$ 1 M) • Successful POC results (Q 2 2024 ) • Breakthrough designation by DRI • Successf
Slide 12: IsletRx Co-development & Projects Pipeline
IsletRx Co - development & Projects Pipeline D EVELOPMENTS T YPE 1 D IABETES 12 In house product using encapsulation: EnCap - IsletRx Plus Collaboration project for h ypo immune gene edited cells : NCX 007 Collaboration project for device: In - Scaffold - IsletRx Plus INDICATION
Slide 13: In House Product Development: Encap-IsletRx Plus Preclinical Efficacy
• Long - term therapeutic effect was achieved in an immunocompetent animal model (C 57 BL/ 6 mice ) • IsletRx Plus cells well protected from host immune system In House Product Development: Encap - IsletRx Plus Preclinical Efficacy Encap - IsletRx Plus treated diabetic mice (STZ) demonstrated balanc
Slide 14: NCX 007 hypoimmune cells and In-Scaffold IsletRx Plus
• Co - Development with TargetGene Biotechnologies Inc. Genome editing to evade immune system recognition allowing graft persistence. • Using precise, validated, gene editing platform, with minimal off - target editing • Enables the production of hypo immune cells for the treatment of Type 1 Diabete
Slide 15: Expansion and differentiation protocols
Expansion and differentiation protocols Potential wide range of cells treating a wide range of diseases. Pluripotent Stem Cell Expansion Bio - Banking GMP quality Starting Material . Clinical - grade Embryonic Stem Cell line Unlimited # of Pluripotent Stem Cell Bio - banks Large scale Key Platform A
Slide 16: Proof of platform product execution from bench to bed
Proof of platform product execution from bench to bed: FDA - approved IND, phase 2 a using AstroRx® cell therapy product for clinical trial in ALS patients 16 72:$5'$&85()257<3( ',$%(7(6
Slide 17: AstroRx Astrocyte Cell Therapy for Neurodegenerative Diseases
Astrocytes - Cell Therapy Treatment for Neurodegenerative Diseases a Validated Platform AstroRx ® AstroRx® Cell Product AstroRx ® has Orphan drug designation from the U.S. Food and Drug Administration ( “ FDA ” ) 17 72:$5'$&85()257<3( ',$%(7(6
Slide 18: Why Use Astrocytes for ALS - AstroRx
Why Use Astrocytes for ALS - AstroRx ® In neurodegeneration, neurons die because their support cells (Astrocytes) fail AstroRx ® contains functional healthy astrocytes to protect ALS - diseased motor neurons using multiple mechanisms of action In ALS, the patient ’ s own astrocytes fail to support m
Slide 19: Follow-up Results Demonstrated a Clinically Meaningful Decline in Disease Progression
3 - month Follow - up Results Demonstrated a Clinically Meaningful Decline in Disease Progression Clinical results are consistent between Cohorts A and B ALSFRS - R slope difference between 3 months pre - and post - treatment in Cohorts A and B GMP manufacturing to human dosing achieved Favorable sa
Slide 20: DOXA (Dual Orexin-Receptor Agonist) Platform
Strategic Enhancements Positioned for potential out - licensing or strategic partnerships Target indications: • Targeting sleep – wake regulation • Rare Sleep Disorders (Narcolepsy, Idiopathic Hypersomnia) • Neurodegenerative / neuroinflammation diseases (such as ߙ - synucleinopathies ) • Diabetes -
Slide 21: Scalability & Clinical Manufacturing Capabilities
21 21 Scalability & Clinical Manufacturing Capabilities 21 From Art to Industry Long - term success in cell therapy through reproducible expansion and differentiation technology, manufacturing systems that are scalable, and cost - efficient Manufacturing Strategy Allogeneic, Off - the - Shelf Model
Slide 22: NewcelX Pipeline Focus – Type 1 Diabetes & CNS Disorders
22 22 IND Preclinical Discovery Indication Target Program Priority Program Type 1 Diabetes Allogeneic Cell Therapy, without chronic immuno supression ITOL102 – IsletRxPlus (Priority Program) Adjacent Programs ALS (Amyotrophic Lateral Sclerosis) Allogeneic Astrocytes AstroRx ® (Platform Validation) N
Slide 23: Patent Protection
Patent Protection Patents in major countries/markets such as the US, EU and other countries providing NewCelX with robust technology protection Methods for differentiating and purifying pancreatic endocrine cells Insulin producing cells derived from pluripotent stem cells Methods of generating glial
Slide 24: The Partnership "Blueprints" Model
The Partnership "Blueprints" Model: We aim to monetize the platform in three ways: 1. Program Licensing: Regional deals for IsletRx / AstroRx 2. Platform Partnerships: Licensing the "Manufacturing Blueprints" to partners (e.g., Pharma wants Dopamine neurons; we build them) 3. Delivery Partnerships :
Slide 25: Leadership Team
Leadership Team 25 Prof. Michel Revel Director & CSO Ronen Twito Executive Chairman & CEO Prof. Ariel Revel, MD Medical Director Alex Zwyer , MBA Director & CBO Eric Konofal , MD, PhD Head of DOXA Program Kfir Molakandov , PhD VP of R&D Omri Hagai CFO Scientific Advisory Board Prof. Tamir Ben Hur M.
Slide 26: Contact
The Circle 6 | P.O. Box CH - 8058 Zurich Switzerland Headquarter in Switzerland : +41 44 512 21 50 Main office in Israel : +972 - 73 - 797 - 1613 info@newcelx.com 26 72:$5'$&85()257<3( ',$%(7(6
Slide 27: References page
References page 1. https://www.diabetesresearchclinicalpractice.com/article/S 0168 - 8227 ( 25 ) 00291 - 8 /fulltext 2. https://diabetesatlas.org/data - by - indicator/type - 1 - diabetes - estimates/people - with - type - 1 - diabetes - 0 - 19 - y/ 3. https://www.diabetesresearchclinicalpractice.co